KPV protocol · PepGuide

Standard

SubQ (gut)

10–40u

0.5–2 mg · Daily

Gut-targeted anti-inflammatory.

SubQ (systemic)

10–20u

0.5–1 mg · Daily

Systemic.

Off

2–4 weeks

Essential break between cycles. Skipping leads to tolerance and diminishing returns.

Phase	How often	Dose	Units	Notes
SubQ (gut)	Daily	0.5–2 mg	10–40u	Gut-targeted anti-inflammatory.
SubQ (systemic)	Daily	0.5–1 mg	10–20u	Systemic.
Off	2–4 weeks	–	–	Essential break between cycles. Skipping leads to tolerance and diminishing returns.

Cycle & timing

Cycle: 4–6 weeks on / 2–4 weeks off. Max: 8 weeks on / 4 weeks off.

Timing: Daily, anytime; SubQ.

Where: SubQ abdomen.

What to expect

Gut symptom improvement within 1–2 weeks; systemic anti-inflammatory within days. Very well tolerated.

How much to buy

For 4-wk @ 2 mg × 7/wk:

12

× 5mg vials

6

× 10mg vials

Men & women

Unisex anti-inflammatory (an α-MSH fragment), same protocol for men and women, no cycle effect.

Dilution calculator

Set to the guide's typical mix for KPV. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

40u

Volume

0.40 mL

Strength

5 mg/mL

Doses per vial

2

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
5 mg	1 mL	5 mg/mL
10 mg	2 mL	5 mg/mL

5 mg: 1 unit = 0.05 mg

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, use within 4 weeks.

Don't use if: Alpha-MSH allergy · Pregnancy · Lactation

Stop if you notice

New skin pigmentation changes
Persistent headache

Side effects

Generally very well tolerated. Rare: mild injection-site reactions.

Drug interactions

Other alpha-MSH agonists (MT-1, MT-2, PT-141): theoretical receptor overlap; redundant rather than additive; Immunosuppressants (cyclosporine, tacrolimus, mycophenolate): KPV’s anti-inflammatory effect may blunt titration markers; coordinate monitoring; Biologics for IBD (infliximab, adalimumab, ustekinumab, vedolizumab): no human data; KPV used as community adjunct but shouldn’t replace prescribed therapy

Labs

Compound-specific: CBC + CMP baseline; no compound-specific markers routinely required

What these labs mean →

Warnings

Limited human data, use for gut conditions is community-standard but not RCT-supported. PCAC RECOMMENDED it for the 503A bulks list, 8–6 (Jul 2026; advisory, non-binding; FDA rulemaking pending).

Patient education

Aseptic technique: alcohol swab the vial septum and the injection site, use a single-use sterile needle for every injection, never share vials or needles between people; Sharps disposal in an FDA-cleared sharps container, never household trash; Cold chain: if a refrigerated peptide reaches room temperature for more than the labeled stability window, discard it; Mark the date of first puncture on every multi-dose vial; Inspect every vial before injection: clear solution (unless labeled otherwise), no particulates, no cloudiness, no color change; Rotate injection sites to avoid lipoatrophy, induration, and infection; Carry a record of what you’re injecting if you need emergency care

These apply on top of the universal safety rules.

Pairs well with

BPC-157

gut healing stack

BPC-157

TB-500

tissue repair

TB-500 (Thymosin Beta-4)

LL-37

additive immune modulation

LL-37

Larazotide

gut barrier complement

Avoid with

Allergy to alpha-MSH analogues

Pregnancy/nursing

KLOW Blend

already contains KPV, would double-dose

KLOW Blend

Can KPV + BPC-157 share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

What it does

α-MSH fragment; preclinical only, no human dosing RCT.

Alpha-MSH C-terminal tripeptide, potent gut and systemic anti-inflammatory via MC1R/MC3R. Tripeptide (Lys-Pro-Val) from alpha-MSH. Binds MC1R/MC3R to suppress NF-κB, IL-6, TNF-α, and promote gut barrier integrity.

References

researchdosing peptidedosages PubMed thepeptidereport peptides.id

From the guide, page 51.